Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penta-STs for Viral and Fungal Infections Post-HSCT
NCT05471661Phase 2Completed
- Sponsor
- G. Papanikolaou General Hospital
- Start
- May 2021
- Primary completion
- May 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pentavalent-specific T cells in adenovirus infection, cytomegalovirus infection (CMV), Epstein-Barr virus infection and 2 more, sponsored by G. Papanikolaou General Hospital. Primary endpoints: Acute Graft-versus-Host Disease at 6 weeks, Chronic Graft-versus-Host Disease at 6 months and 7 more. Started May 2021; status: completed.
02
Drugs
pentavalent-specific T cells
03
Conditions
adenovirus infectioncytomegalovirus infection (CMV)Epstein-Barr virus infectionBK virus infectionaspergillosis
Beyond the preview
Go deeper on NCT05471661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05471661.